The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Gout Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.
Some of the key takeaways from the Gout Pipeline Report:
- Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years.
- Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others, are developing therapies for the Gout treatment
- Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others are expected to have a significant impact on the Gout market in the coming years.
- In February 2024, PK Med, a biotechnology company headquartered in France, has obtained clearance from the US Food and Drug Administration (FDA) to progress its injectable gout treatment, PKM-01, directly into Phase II clinical trials, bypassing Phase I studies. The Phase II trial will assess three different doses of PKM-01, a combination therapy consisting of controlled-release colchicine with ropivacaine, an anesthetic. This prospective, randomized study aims to determine the optimal dosage of the treatment for further advancement into Phase III trials.
- In March 2023, Selecta Biosciences, Inc. revealed favorable outcomes from the Phase 3 DISSOLVE I & II trials, comparing SEL-212 against a placebo. SEL-212 aims to address chronic refractory gout.
Gout Overview
An extremely painful type of inflammatory arthritis that is common is gout. Usually, it only affects one joint at a time, most commonly the big toe joint. Periods of increased symptom severity are referred to as flares, and periods with no symptoms are referred to as remission.
Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight
Emerging Gout Drugs Under Different Phases of Clinical Development Include:
- TJC-0434: TaiwanJ Pharmaceuticals
- NC-2700: Nippon Chemiphar
- Research Program: HemoShear Horizon Therapeutics plc
- NC-2500: Nippon Chemiphar
- PRX-115: Protalix BioTherapeutics
- HZN-457: Horizon Therapeutics plc
- AR-882: Arthrosi Therapeutics
- DYV700: Dyve Biosciences
- LC350189: LG Chem
- SHR-4640: Jiangsu Hengrui Medicine Co.
- SEL-212: Selecta Biosciences Inc
- D-0120 + Allopurinol: InventisBio Co., Ltd
- ALLN-346: Allena Pharmaceuticals
- Dapansutrile: Olatec Therapeutics LLC
- SAP001: Shanton Pharma Co., Ltd.
- Tigulixostat: LG Chem
Gout Route of Administration
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Gout Molecule Type
Gout Products have been categorized under various Molecule types, such as
- Protein
- Small interfering RNA
- Small molecule
- Product Type
Gout Pipeline Therapeutics Assessment
- Gout Assessment by Product Type
- Gout By Stage and Product Type
- Gout Assessment by Route of Administration
- Gout By Stage and Route of Administration
- Gout Assessment by Molecule Type
- Gout by Stage and Molecule Type
DelveInsight’s Gout Report covers around 40+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies
Some of the key companies in the Gout Therapeutics Market include:
Key companies developing therapies for Gout are – Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.
Gout Pipeline Analysis:
The Gout pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
- Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Gout drugs and therapies
Gout Pipeline Market Drivers
- The rise in the prevalence of Gout, Novel urate-lowering agents are some of the important factors that are fueling the Gout Market.
Gout Pipeline Market Barriers
- However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.
Scope of Gout Pipeline Drug Insight
- Coverage: Global
- Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others
- Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others
- Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies
- Gout Market Dynamics: Gout market drivers and Gout market barriers
Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials
Table of Contents
1. Gout Report Introduction
2. Gout Executive Summary
3. Gout Overview
4. Gout- Analytical Perspective In-depth Commercial Assessment
5. Gout Pipeline Therapeutics
6. Gout Late Stage Products (Phase II/III)
7. Gout Mid Stage Products (Phase II)
8. Gout Early Stage Products (Phase I)
9. Gout Preclinical Stage Products
10. Gout Therapeutics Assessment
11. Gout Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gout Key Companies
14. Gout Key Products
15. Gout Unmet Needs
16 . Gout Market Drivers and Barriers
17. Gout Future Perspectives and Conclusion
18. Gout Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/